Vir Biotechnology, Inc.
(NASDAQ : VIR)

( )
VIR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.55%582.522.7%$671.55m
AMGNAmgen, Inc. -0.64%223.461.3%$579.11m
GILDGilead Sciences, Inc. 0.08%60.011.0%$578.78m
VRTXVertex Pharmaceuticals, Inc. 2.43%212.191.9%$533.31m
MRNAModerna, Inc. 0.61%70.670.0%$451.00m
ILMNIllumina, Inc. 0.84%321.743.5%$422.57m
EXASEXACT Sciences Corp. 23.04%131.1220.7%$294.14m
NVAXNovavax, Inc. 2.53%89.5996.5%$273.94m
ALXNAlexion Pharmaceuticals, Inc. -0.63%120.002.0%$268.90m
BIIBBiogen, Inc. -0.57%255.301.7%$264.14m
BNTXBioNTech SE 1.23%83.950.0%$211.49m
SRNESorrento Therapeutics, Inc. -2.65%7.711.4%$151.30m
SGENSeagen Inc. 0.56%196.926.0%$150.43m
CRSPCRISPR Therapeutics AG 4.24%98.120.6%$126.32m
TXG10X Genomics, Inc. 1.20%142.930.0%$104.03m

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.